Close Menu

NEW YORK – NeoGenomics today reported a 50 percent year-over-year uptick in its second quarter revenues with strong growth in both its clinical services and pharma services businesses.

For the three months ended June 30, total revenues reached $101.7 million, up from $67.7 million in Q2 2018, and beating analysts' average estimate of $97.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.